Medical Week Daily

Medical news today: Saturday, October 31, 2026

Congo Ebola deaths exceed 5,000 as healthcare costs trouble older Americans and new diagnostics advance

Get tomorrow's issue in your inbox.

  1. 01

    Congo Ebola outbreak passes 5,000 deaths as cases spread across the region

    Source: Associated Press

    Congolese health ministry data cited by AP show 10,351 people infected and 5,026 deaths in the ongoing Bundibugyo Ebola outbreak. Cases have also been recorded in neighboring and other African countries. Health workers face contact-tracing gaps, attacks and resource shortages.

    Why it mattersThe spread underscores the need for coordinated case detection, infection prevention and support for responders. Unlike the Zaire Ebola virus, the Bundibugyo virus has no approved specific vaccine or treatment. More on Approvals & regulatory →

  2. 02

    Older US adults worry about Medicare costs and medication affordability ahead of elections

    Source: Associated Press

    AP reports that older US voters are closely watching changes to Medicare premiums, drug coverage and insurer participation as healthcare costs strain household budgets. Caregiving expenses and skipped medication due to cost remain prominent concerns.

    Why it mattersCoverage and affordability can determine whether older patients maintain treatment; changes in benefits and formularies warrant careful review before enrollment decisions.

  3. 03

    Investigational vaginal swab could reduce the need for invasive endometrial biopsies

    Source: Medical Xpress / HealthDay

    A vaginal swab test under investigation at 16 US sites aims to detect molecular signals from endometrial cancer in symptomatic women. The approach is still in clinical evaluation; positive results and persistent symptoms require appropriate medical follow-up.

    Why it mattersA less-invasive first-line test could improve the experience of assessing postmenopausal bleeding, but accuracy, independent validation and follow-up protocols must be established before broad use. More on Oncology →

  4. 04

    Lilly reports retatrutide outperformed Ozempic 2 mg in a phase 3 diabetes trial

    Source: Eli Lilly

    The company said participants on retatrutide reduced HbA1c by about 2.2 percentage points and body weight by 19.5% to 20.9% after 80 weeks, versus 1.8 points and 9.4% on semaglutide 2 mg. These are topline company-reported results, not an approval decision.

    Why it mattersThe results may influence future diabetes and obesity treatment development if confirmed by full peer-reviewed data and regulators. Gastrointestinal side effects and discontinuation rates remain relevant to benefit-risk assessment. More on Approvals & regulatory →

  5. 05

    Phase 3 study finds retatrutide reduced sleep-apnea events in patients with obesity

    Source: New England Journal of Medicine

    Two randomized phase 3 trials published in NEJM found that investigational retatrutide reduced the apnea-hypopnea index more than placebo over 80 weeks in adults with moderate-to-severe obstructive sleep apnea and elevated BMI.

    Why it mattersThe findings suggest potential benefits beyond weight loss, but retatrutide remains investigational, and patients should not replace established apnea therapies based on these results alone. More on Obesity & metabolic →

New here? How to read this digest
Each story links to its original source. "Why it matters" explains what it means for you in plain language. This is news, not medical advice: talk to your doctor about your own care. Browse all topics or the archive.

More recent digests

Free daily email

The day's approvals, safety signals and trials, in five minutes.

Join the list with just your email. You can also follow the RSS feed.

Free, one field, no spam. We only use your address to send Medical Week Daily and never sell it. Ask to be removed any time via the contact page. See the privacy note.

For information and education only. Not medical advice. Medical Week Daily summarizes published health news in plain language for general readers. It does not replace advice from your doctor, product labeling or regulatory documents. Always consult a qualified healthcare professional about your own care, and check the original source. Full medical disclaimer